The FDA announced new advisory committee meetings under leadership changes, with Replimune and Capricor among the programs resurfacing after earlier controversy. Replimune’s oncolytic immunotherapy RP1 for advanced melanoma is in the next regulatory decision window, following two prior FDA rejections tied to adequacy of evidence for accelerated approval. A late-July advisory committee is expected to precede an FDA decision by early August. For the field, the renewed adcom emphasis signals that contested oncology applications—especially those resubmitted after regulatory disagreement—are likely to face heightened committee scrutiny under the current FDA operating posture.